June 25, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Arvinas (Nasdaq:ARVN), a pharmaceutical company inventing the famous proprietary PROTAC® protein degraders.
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Their proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been “undruggable” by traditional approaches.
Complete Omics is proud to work with Arvinas and our mutual efforts will help bring numerous novel cancer therapeutics to reality.
